SECsense Logo

Design Therapeutics, Inc. 8-K Report: Key Updates for January 13, 2025

$DSGN
Form 8-K
Filed on: 2025-01-13
Source
Design Therapeutics, Inc. 8-K Report: Key Updates for January 13, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Name: Design Therapeutics, Inc.
  • CIK (Central Index Key): 0001807120
  • SEC File Number: 001-40288
  • EIN (Employer Identification Number): 82-3929248
  • Address: 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011
  • Phone Number: (858) 293-4900
  1. Report Type:
  • Form: 8-K (which is used for current reports by companies to announce major events that shareholders should know about)
  1. Report Period:
  • Start Date: January 13, 2025
  • End Date: January 13, 2025
  1. Securities Information:
  • Common Stock Par Value: $0.0001 per share
  • Stock Symbol: DSGN
  • Exchange: NASDAQ
  1. Filing Context:
  • The document is part of an XBRL (eXtensible Business Reporting Language) filing, which is a standardized format for financial data.

Insights:

  • The report is a current event filing (Form 8-K), suggesting that Design Therapeutics, Inc. may have significant news or events to disclose as of January 13, 2025.
  • The company is publicly traded on NASDAQ under the ticker symbol DSGN, indicating it operates in a regulated environment and must comply with SEC filing requirements.
  • The specific date of the report (January 13, 2025) could indicate an immediate event or announcement that may be relevant for investors and stakeholders.
  • The low par value of the common stock could signal a startup or growth-stage company, which is common in biotech firms.

This information can provide stakeholders with insights into the company's operational status and financial health as of the reporting date.